Suggestion by Irakrakow on 2008-01-24 01:26:21
As you point out, Insulet has an innovative method of delivering insulin to diabetes patients. The OmniPod System features only two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provide for virtually pain-free automated cannula insertion, communicate wirelessly and integrate a blood glucose meter. Diabetes is a huge market. There are 300,000 current insulin pumpers in the US.
Insulet is a startup which did its IPO in May 2007, with a secondary IPO in November, 2007. Have you compared the OmniPod with the Medtronic minimed Paradigm system, which markets a real time insulin pump? According to their 3rd quarter 2007 conference call, Insulet has an development agreement with Abbott Labs for continuous glucose monitoring. PODD is also doing offshore production of their OmniPods in China. They have a manufacturing agreement with Flextronics as well. Could you analyze whether or not the company will be profitable before its cash from the IPO runs out?
http://www.myomnipod.com/products/ http://insulinpumpdemystified.blogspot.com/2006/05/allure-of-omnipodat-least-on-film.html http://www.bloggingstocks.com/2007/10/02/analyst-initiations-cypb-bac-podd-tleo-and-vocs/ http://www.minimed.com/products/insulinpumps/ http://www.seekingalpha.com/article/35397-three-healthcare-ipos-eurand-insulet-corporation-skilled-healthcare-group http://biz.yahoo.com/prnews/080107/nym062.html?.v=96
Add comments or discussion related to this suggestion here.